Canada approves three more biosimilars in 2022

Biosimilars/News | Posted 28/05/2024 post-comment0 Post your comment

Since the last update in June 2022, Health Canada has approved three more biosimilars (Myxredlin, Rymti, Elonox) in 2022 [1].

Health Canada V13I20

The biosimilars approved in the second half of 2022 are: 

– Baxter’s MYXREDLIN, biosimilar of Novo Nordisk’s NOVOLIN (human insulin, recombinant) – authorized on 3 August 2022
– Lupin Pharma’s RYMTI, biosimilar of Immunex’s ENBREL (etanercept) – authorized on 13 September 2022 [2]
 Fresenius Kabi’s ELONOX and ELONOX HP, biosimilars of Sanofi’s LOVENOX and LOVENOX HP (enoxaparin sodium) – Authorizeon 26 October 2022

Myxredlin (insulin human in 0.9% sodium chloride injection) is available in a standardized concentration of 100 units/100 mL in a flexible plastic container indicated to improve glycaemic control in adults and paediatric patients with diabetes mellitus.

Lupin’s Rymti (etanercept) is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis, and is available as an injectable easy-to-use pre-filled pen and a pre-filled syringe [2].

Elonox (enoxaparin sodium) is the second biosimilar product introduced in Canada by Fresenius Kabi. Elonox and Elonox HP are indicated for deep vein thrombosis and comes in seven pre-filled syringe dosages. All are now available and listed on every provincial formulary across Canada.

The Health Canada authorization of Elonox, was based on the evidence submitted to Health Canada including analytical, and clinical data in healthy volunteers and patients.  Indications have been granted on the basis of similarity between the biosimilar and the reference biological drug. 

By end of March 2024, Health Canada had approved 59 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor (G-CSF), insulin, monoclonal antibodies and tumour necrosis factor (TNF)-inhibitor, for use in Canada [3].

Related article
First denosumab biosimilars approved in Canada and the US

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. GaBI Online - Generics and Biosimilars Initiative. Canada approves five biosimilars in last seven months [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/news/canada-approves-five-biosimilars-in-last-seven-months
2. GaBI Online - Generics and Biosimilars Initiative. Canada approves etanercept biosimilar Rymti [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/news/canada-approves-etanercept-biosimilar-rymti
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Canada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-canada

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
EMA recommends approval of bevacizumab Lytenava
Blue eye with data points
Biosimilars/News Posted 22/05/2024
Three more biosimilar approvals in Canada in 2023
18794124_l
Biosimilars/News Posted 14/05/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010